Variation in AKR1C3, which encodes the neuroactive steroid synthetic enzyme 3α-HSD type 2 (17β-HSD type 5), moderates the subjective effects of alcohol

被引：0
|
作者：
Verica Milivojevic
Richard Feinn
Henry R. Kranzler
Jonathan Covault
机构：
[1] University of Connecticut School of Medicine,Alcohol Research Center, Department of Psychiatry
[2] Quinnipiac University,Department of Medical Sciences, Frank Netter School of Medicine
[3] University of Pennsylvania Perelman School of Medicine,Department of Psychiatry
[4] Philadelphia VAMC,VISN4 MIRECC
[5] University of Connecticut Health Center,Department of Neuroscience
来源：
Psychopharmacology | 2014年 / 231卷
关键词：
Psychiatric Genetics; 3α-HSD; 17β-HSD; Alcohol dependence; Polymorphism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3597 / 3608
页数：11
相关论文
共 50 条
  • [21] Discovery of a bifunctional Type 5 17b-hydroxysteroid dehydrogenase (AKR1C3) inhibitor and androgen receptor antagonist
    Adeniji, Adegoke O.
    Twenter, Barry M.
    Winkler, Jeffrey D.
    Penning, Trevor M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [22] Decreased Expression of Type 5 17 β-Hydroxysteroid Dehydrogenase (AKR1C3) Protein Identified in Human Diabetic Skin Tissue
    Cho, Moon-Kyun
    ANNALS OF DERMATOLOGY, 2013, 25 (04) : 423 - 427
  • [23] Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)
    Adeniji, Adegoke O.
    Twenter, Barry M.
    Byrns, Michael C.
    Jin, Yi
    Winkler, Jeffrey D.
    Penning, Trevor M.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1464 - 1468
  • [24] Selective Inhibition of Human Type-5 17β-Hydroxysteroid Dehydrogenase (AKR1C3) by Baccharin, a Component of Brazilian Propolis
    Endo, Satoshi
    Matsunaga, Toshiyuki
    Kanamori, Ayano
    Otsuji, Yoko
    Nagai, Hiroko
    Sundaram, Krithika
    El-Kabbani, Ossama
    Toyooka, Naoki
    Ohta, Shozo
    Hara, Akira
    JOURNAL OF NATURAL PRODUCTS, 2012, 75 (04): : 716 - 721
  • [25] 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3)
    Gazvoda, Martin
    Beranic, Natasa
    Turk, Samo
    Burja, Bojan
    Kocevar, Marijan
    Rizner, Tea Lanisnik
    Gobec, Stanislav
    Polanc, Slovenko
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 62 : 89 - 97
  • [26] Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase);: immunohistochemical detection in breast and prostate
    Lin, HK
    Steckelbroeck, S
    Fung, KM
    Jones, AN
    Penning, TM
    STEROIDS, 2004, 69 (13-14) : 795 - 801
  • [27] 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: Highly Potent and Selective Inhibitors of the Type 5 17-β-Hydroxysteroid Dehydrogenase AKR1C3
    Jamieson, Stephen M. F.
    Brooke, Darby G.
    Heinrich, Daniel
    Atwell, Graham J.
    Silva, Shevan
    Hamilton, Emma J.
    Turnbull, Andrew P.
    Rigoreau, Laurent J. M.
    Trivier, Elisabeth
    Soudy, Christelle
    Samlal, Sharon S.
    Owen, Paul J.
    Schroeder, Ewald
    Raynham, Tony
    Flanagan, Jack U.
    Denny, William A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (17) : 7746 - 7758
  • [28] Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma
    Lewis, MJ
    Wiebe, JP
    Heathcote, JG
    BMC CANCER, 2004, 4 (1)
  • [29] Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma
    Michael J Lewis
    John P Wiebe
    J Godfrey Heathcote
    BMC Cancer, 4
  • [30] An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies
    Byrns, Michael C.
    Steckelbroeck, Stephan
    Penning, Trevor M.
    BIOCHEMICAL PHARMACOLOGY, 2008, 75 (02) : 484 - 493
12345